IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter
Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules.
Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Change from offer price to today
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:KLRA
Key valuation ratios and metrics
Balance sheet strength and liquidity
Margins and return on capital
Street consensus and price targets
Volatility versus the market
Historical financial performance
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-05-13 | $22.50 | $23.39 | $21.00 | $21.11 | $21.11 | -1.39 | 349,600 |
| 2026-05-12 | $23.41 | $23.62 | $22.13 | $22.30 | $22.30 | -1.11 | 359,200 |
| 2026-05-11 | $21.52 | $23.20 | $21.52 | $22.93 | $22.93 | +1.41 | 482,900 |
| 2026-05-08 | $22.52 | $24.27 | $21.22 | $21.47 | $21.47 | -1.05 | 446,200 |
| 2026-05-07 | $24.66 | $24.74 | $22.44 | $22.47 | $22.47 | -2.19 | 279,900 |
| 2026-05-06 | $24.22 | $25.70 | $23.88 | $24.70 | $24.70 | +0.48 | 531,200 |
| 2026-05-05 | $25.01 | $25.50 | $23.80 | $24.26 | $24.26 | -0.75 | 425,200 |
| 2026-05-04 | $24.95 | $25.32 | $24.22 | $25.09 | $25.09 | +0.14 | 729,900 |
| 2026-05-01 | $25.02 | $25.55 | $24.04 | $25.15 | $25.15 | +0.13 | 551,200 |
| 2026-04-30 | $24.51 | $25.41 | $24.12 | $25.00 | $25.00 | +0.49 | 462,500 |
| 2026-04-29 | $23.95 | $25.00 | $23.28 | $24.76 | $24.76 | +0.81 | 681,100 |
| 2026-04-28 | $23.27 | $24.32 | $22.95 | $23.82 | $23.82 | +0.55 | 461,400 |
| 2026-04-27 | $22.26 | $23.64 | $20.87 | $23.51 | $23.51 | +1.25 | 1,070,500 |
| 2026-04-24 | $24.70 | $25.30 | $22.10 | $22.47 | $22.47 | -2.23 | 1,209,800 |
| 2026-04-23 | $24.25 | $25.48 | $24.13 | $25.08 | $25.08 | +0.83 | 3,995,800 |
| 2026-04-22 | $25.17 | $25.75 | $23.65 | $24.30 | $24.30 | -0.87 | 891,900 |
| 2026-04-21 | $24.87 | $25.79 | $23.70 | $25.22 | $25.22 | +0.35 | 843,100 |
| 2026-04-20 | $26.50 | $28.23 | $23.69 | $24.61 | $24.61 | -1.89 | 1,341,000 |
| 2026-04-17 | $26.00 | $27.50 | $23.70 | $26.00 | $26.00 | 0.00 | 8,114,300 |
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13D | Apr 23, 2026 | Filing |
| SCHEDULE 13D | Apr 23, 2026 | Filing |
| 8-K | Apr 20, 2026 | Current Report |
| 424B4 | Apr 17, 2026 | Prospectus |
| S-8 | Apr 17, 2026 | Securities to be offered to employees in employee benefit plans |
| EFFECT | Apr 16, 2026 | Notice of Effectiveness |
| S-1MEF | Apr 16, 2026 | Registration adding securities to prior Form S-1 registration |
| CERT | Apr 15, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | Apr 14, 2026 | Registration of securities |
| S-1/A | Apr 13, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
Contact and headquarters details
Key executives and officers
Ronald C. Renaud, Jr.
President, Chief Executive Officer and Director
Scott Akamine
Chief Legal Officer and Secretary
Paul Burgess
Chief Operating Officer and Chief Business Officer
Paula Cloghessy
Chief People Officer
Jamie Coleman
Chief Commercial Officer
Douglas Pagán
Chief Financial Officer
Scott Wasserman, M.D.
Chief Medical Officer
John F. Milligan, Ph.D.
Chairman
Frank Clyburn, Jr.
Director
Michael Gladstone
Director

USD · NASDAQ:KLRA
Issue Size
$625.00M
Price Range
$16.00
Shares
129.54M o/s · 39.06M offered
Listing Price
$26.00
Listing date
Apr 17, 2026
Sector
Healthcare